申请人:Merrell Dow Pharmaceuticals Inc.
公开号:US05047534A1
公开(公告)日:1991-09-10
Xanthine derivative which act selectively at adenosine receptors and which act in general as adenosine antagonists are disclosed. From in vitro studies it is known that specific physiological effects can be distinguished as a result of this selectively and that adenosine receptor activity in vitro correlates with adenosine receptor activity in vivo. Pharmaceutical preparations of the subject compounds can be prepared on the basis of the selective binding activity of the compounds disclosed herein which will enhance certain physiological effects while minimizing others, such as decreasing blood pressure without decreasing heart rate.
本发明揭示了在腺苷受体上选择性作用的黄嘌呤衍生物,通常作为腺苷拮抗剂。从体外研究中已知,由于这种选择性,可以区分特定的生理效应,并且体外的腺苷受体活性与体内的腺苷受体活性相关。根据本文披露的化合物的选择性结合活性,可以制备这些化合物的药物制剂,这将增强某些生理效应,同时最小化其他效应,例如降低血压而不降低心率。